Back to MAIN AGENDA

Day 3: Friday March 24, 2017

Organizers: Ahmet Erdemir (erdemira@ccf.org), Lealem Mulugeta (lealem@insilico-labs.com), Joy Ku (joyku@stanford.edu)

Organizers' biographies:

Introductory Presentation:

Objectives of Theme 6

The overall objective of this session is to provide a forum for the U01 awardees and the broad IMAG/MSM consortium to learn from each others' collective experiences on establishing credibility in modeling and simulation. The specific goals of the session are

1. To provide the new U01 awardees the opportunity to give an overview of their projects' Model Credibility Plan
2. To give the broad IMAG/MSM community the opportunity to provide feedback on the U01 awardees' Model Credibility Plan
3. To provide a networking opportunity to match U01 awardees with third-party evaluators

Speakers:

Theme 6 Part 1 - 1:00-2:30pm

1:00 - 1:10 pm: DAVID BASANTA GUTIERREZ and CONOR LYNCH - Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer

1:10 - 1:20 pm: WILLIAM CANNON and JAY DUNLAP - Multiscale Modeling of Circadian Rhythms

1:20 - 1:30 pm: XIAOBO ZHOU and YUNZHI YANG - Systems Modeling Guided Bone Regeneration

1:30 - 1:40 pm: TERENCE SANGER and SIMON GISZTER - Multiscale models of neural population control in spinal cord

1:40 - 1:50 pm: MICHAEL HENSON, ERIK HERZOG and KEVREKIDIS, YANNIS G. - Multiscale Modeling of the Mammalian Circadian Clock: The Role of GABA Signaling

1:50 - 2:00 pm: DENISE KIRSCHNER, VERONIQUE DARTOIS, JOANNE FLYNN and JENNIFER LINDERMAN - A Multi-scale systems pharmacology approach to TB therapy

2:00 - 2:30 pm: Panel Discussion

Theme 6 Part 2 - 3:00-4:15pm

3:00 - 3:10 pm: SCOTT DIAMOND - Multiscale Analysis of Trauma

3:10 - 3:20 pm: TIMOTHY CORCORAN and ROBERT PARKER - Building Multilevel Models of Therapeutic Response in the Lungs

3:20 - 3:30 pm: SILVIA BLEMKER and SHAYN PEIRCE-COTTLER - Multiscale Modeling for Treatment Discovery in Duchenne Muscular Dystrophy

3:30 - 3:40 pm: BRUCE LEE - Virtual Population Obesity Prevention (VPOP) Labs: Computational, Multi-Scale Models for Obesity Solutions

3:40 - 3:50 pm: DANNY BLUESTEIN - Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis

3:50 - 4:20 pm: Panel Discussion

Instructions to the Presenters

Each speaker is asked to give a 10 minute presentation on their projects' Model Credibility Plan. While not obligatory, the speakers are encouraged to respond to the following guidelines on presentation content in order to have an effective and focused session on credibility in modeling and simulation. The speakers are asked to include:

1. A title slide, which includes the Project Title and Project Start Date.
2. A slide on context of use (or intended utility) and audience of models in the project
3. A description of key components of the Model Credibility Plan
4. Timeline and milestones of the Model Credibility Plan
5. Year 1 progress of the Model Credibility Plan (accomplishments or planned activities)
6. Challenges and opportunities with the Model Credibility Plan
7. Uniqueness of the Model Credibility Plan (e.g. what are some special considerations built into the plan resulting from specific modeling/simulation situation?)
8. Any crossover with the perspectives of the Committee on Credible Practice of Modeling and Simulation in Healthcare (see https://simtk.org/websvn/wsvn/cpms/doc/posters/fmd_2015.pdf)
9. Specific requirements for third party evaluation (e.g. desirable evaluator capabilities)
10. Questions to IMAG/MSM (to request feedback)

Panel Discussion Purpose and Format

Session will be concluded with a 30 minute panel discussion to collectively elaborate on:

• Lessons learned in development and implementation of Model Credibility Plans
• Feedback from IMAG and MSM on proposed model credibility plans
• Implementation of third party evaluation process and potential implementation challenges

To cultivate productive discussion during the panel and via online comments, all PIs are asked to post on their designated wiki page:

1. A PDF copy of Model Credibility Plan
2. The components of the model with a clear description of context of use for (a) the model developer and (b) model evaluators
3. The availability of the model (What will be delivered to third party evaluators? When and how?)
4. Specific requirements for third party evaluators (desirable skills, access to software

Add your questions and comments here!